Critical shortages of imaging equipment and qualified radiologists left an estimated 56,000 angina patients without access to potentially lifesaving computed tomography (CT) scans last year, the Royal College of Radiologists and British Society of Cardiovascular Imaging announced Nov. 8.

For patients with nonvalvular atrial fibrillation (AFib), taking a direct oral anticoagulant (DOAC) instead of warfarin may cut the risk of dementia by 15 to 20 percent, according to a large database study published Nov. 2 in the Journal of the American Heart Association.

Climbing rates of violent crime could trigger blood pressure (BP) spikes within nearby communities—particularly among individuals living in what are considered “safe” neighborhoods—according to a study of 50,000 adults living in Chicago.

Poor health literacy could mean an increased risk of death for patients hospitalized with acute decompensated heart failure (ADHF), according to a study published in Mayo Clinic Proceedings Nov. 7.

A new study in JAMA Cardiology showed patients’ risk perceptions and willingness to accept therapy are influenced by the type of estimate they’re presented with and how that information is organized.

Medtronic announced U.S. Food and Drug Administration (FDA) approval to begin a clinical trial to evaluate the Symplicity Spyral renal denervation system in patients with high blood pressure (hypertension) who are already prescribed anti-hypertension medications.

A physician with Pulse Cardiology in San Bernardino, California, has been accused of racist behavior after allegedly criticizing a patient for not speaking English, Yahoo Finance reported Nov. 6.

While many Americans were fixated on the Congressional races during the Nov. 6 midterm elections, the American Heart Association and CEO Nancy Brown kept an eye on ballot measures with implications for cardiovascular health.

A clinical and economic analysis of PCSK9 inhibitors in Canadian patients with atherosclerotic cardiovascular disease (ASCVD) is solidifying physician concerns that the lipid-lowering drugs might be too inaccessible—or too pricey—to benefit the average heart patient.

Roux-en-Y gastric bypass (RYGB) is linked to greater weight loss compared to two other bariatric procedures but also the highest risk of adverse events in the short term, researchers reported in the Annals of Internal Medicine.